Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University
Publications
Papers and books
Kobayashi R, Nakamura T, Naganuma F, Harada R, Morioka D, Kanoto M, Furumoto S, Kudo Y, Kabasawa T, Otani K, Futakuchi M, Kawakatsu S, Okamura N. In vivo [18F]THK-5351 imaging detected reactive astrogliosis in argyrophilic grain disease with comorbid pathology: A clinicopathological study. J Neuropathol Exp Neurol. 2023 (in press)
Villemagne VL, Harada R, Dore V, Furumoto S, Mulligan R, Kudo Y, Burnham S, Krishnadas N, Bozinovski S, Huang K, Lopresti BJ, Yanai K, Rowe CC, Okamura N. First-in-human evaluation of 18F-SMBT-1, a novel 18F-labeled MAO-B PET tracer for imaging reactive astrogliosis. J Nucl Med. 2022; 63: 1551-1559.
Villemagne VL, Harada R, Dore V, Furumoto S, Mulligan R, Kudo Y, Burnham S, Krishnadas N, Bourgeat P, Xia Y, Laws S, Bozinovski S, Huang K, Ikonomovic MD, Fripp J, Yanai K, Okamura N, Rowe CC. Assessing reactive astrogliosis with 18F-SMBT-1 across the Alzheimer’s disease spectrum. J Nucl Med. 2022; 63: 1560-1569.
Horimoto Y, Hayashi E, Okamura N, Inagaki A, Yasui K, Uchida Y, Ito Y, Iida A, Sato C, Anan C, Suzuki A, Tajima T, Hibino H, Kabasawa H, Matsukawa N. Middle Cerebellar Peduncle in Early Stage of Multiple System Atrophy: A THK5351 PET Study. Mov Disord. 2022; 37: 1957-1959.
Sakurai K, Nihashi T, Kimura Y, Iwata K, Ikenuma H, Arahata Y, Okamura N, Yanai K, Akagi A, Ito K, Kato T, Nakamura A, Group MS. Age-related increase of monoamine oxidase B in amyloid-negative cognitively unimpaired elderly subjects. Ann Nucl Med. 2022; 36: 777-784.
Kang S, Kim J, Lee SY, Okamura N, Chang KA. MicroPET imaging assessment of brain tau and amyloid deposition in 6 x Tg Alzheimer’s disease model mice. Int J Mol Sci. 2022; 23: 5485.
Uchida Y, Kan H, Sakurai K, Horimoto Y, Hayashi E, Iida A, Okamura N, Oishi K, Matsukawa N. APOE ?4 dose associates with increased brain iron and β-amyloid via blood-brain barrier dysfunction. J Neurol Neurosurg Psychiatry. 2022 doi: 10.1136/jnnp-2021-328519.
Otsuka R, Naganuma F, Nakamura T, Miwa H, Nakayama-Naono R, Matsuzawa T, Komatsu Y, Sato Y, Takahashi Y, Tatsuoka-Kitano H, Yanai K, Yoshikawa T. Contribution of astrocytic histamine N-methyltransferase to histamine clearance and brain function in mice. Neuropharmacology 2022; 212: 109065.
Nakamura T, Naganuma F, Kudomi U, Roh S, Yanai K, Yoshikawa T. Oral histidine intake improves working memory through the activation of histaminergic nervous system in mice. Biochem Biophys Res Commun2022; 609: 141-148.
Okamura N, Harada H. (2022) PET Imaging of Amyloid and Tau in Alzheimer’s Disease. In: Mori, N. (eds) Aging Mechanisms II . Springer, Singapore. https://doi.org/10.1007/978-981-16-7977-3_19
Li Y, Rusinek H, Butler T, Glodzik L, Pirraglia E, Babich J, Mozley PD, Nehmeh S, Pahlajani S, Wang X, Tanzi EB, Zhou L, Strauss S, Carare RO, Theise N, Okamura N, de Leon MJ. Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease. Fluids Barriers CNS. 2022; 19: 21.
Harada R, Furumoto S, Kudo Y, Yanai K, Villemagne VL, Okamura N. Imaging of reactive astrogliosis by positron emission tomography. Front Neurosci. 2022; 16: 807435.
Harada R, Shimizu Y, Du Y, Ishikawa Y, Iwata R, Kudo Y, Yanai K, Okamura N, Furumoto S. The role of chirality of [18F]SMBT-1 in imaging of monoamine oxidase-B. ACS Chem Neurosci. 2022; 13: 322-329.
Ezura M, Kikuchi A, Okamura N, Ishiki A, Hasegawa T, Harada R, Watanuki S, Funaki Y, Hiraoka K, Baba T, Sugeno N, Yoshida S, Kobayashi J, Kobayashi M, Tano O, Ishiyama S, Nakamura T, Nakashima I, Mugikura S, Iwata R, Taki Y, Furukawa K, Arai H, Furumoto S, Tashiro M, Yanai K, Kudo Y, Takeda A, Aoki M. 18F-THK5351 positron emission tomography imaging in neurodegenerative tauopathies. Front Aging Neurosci. 2021; 13: 761010.
Nihashi T, Sakurai K, Kato T, Iwata K, Kimura Y, Ikenuma H, Yamaoka A, Takeda A, Arahata Y, Washimi Y, Suzuki K, Bundo M, Sakurai T, Okamura N, Yanai K, Ito K, Nakamura A; MULNIAD Study Group. Patterns of distribution of 18F-THK5351 positron emission tomography in Alzheimer’s disease continuum. J Alzheimers Dis. 2021 doi: 10.3233/JAD-215024.
Naganuma F, Nakamura T, Kuroyanagi H, Tanaka M, Yoshikawa T, Yanai K, Okamura N. Chemogenetic modulation of histaminergic neurons in the tuberomamillary nucleus alters territorial aggression and wakefulness. Sci Rep. 2021; 11: 17935.
Filip T, Mairinger S, Neddens J, Sauberer M, Flunkert S, Stanek J, Wanek T, Okamura N, Langer O, Hutter-Paier B, Kuntner C. Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling. Alzheimers Res Ther. 2021; 13: 175.
Uchida Y, Horimoto Y, Shibata H, Kuno T, Usami T, Takada K, Iida A, Ueki Y, Okamura N, Matsukawa N. Occipital tau deposition and astrogliosis after traumatic brain injuries in a kendo player. Neurol Clin Pract. 2021; 11: e579-e581.
Alzghool OM, Rokka J, López-Picón FR, Snellman A, Helin JS, Okamura N, Solin O, Rinne JO, Haaparanta-Solin M. (S)-[18F]THK5117 brain uptake is associated with Aβ plaques and MAO-B enzyme in a mouse model of Alzheimer’s disease. Neuropharmacology. 2021; 196: 108676.
Naganuma F, Yoshikawa T. Organic cation transporters in brain histamine clearance: Physiological and psychiatric implications. Handb Exp Pharmacol. 2021 DOI: 10.1007/164_2021_447
Lee HJ, Lee EC, Seo S, Ko KP, Kang JM, Kim WR, Seo HE, Lee SY, Lee YB, Park KH, Yeon BK, Okamura N, Na DL, Seong JK, Noh Y. Identification of heterogeneous subtypes of mild cognitive impairment using cluster analyses based on PET imaging of tau and astrogliosis. Front Aging Neurosci. 2021; 12: 615467.
Morito T, Harada R, Iwata R, Du Y, Okamura N, Kudo Y, Yanai K. Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody. Sci Rep. 2021; 11: 2588.
Yosikawa T, Nakamura T, Yanai K. Histaminergic neurons in the tuberomammillary nucleus as a control centre for wakefulness. Br J Pharmacol. 2021; 178: 750-769.
Harada R, Hayakawa Y, Ezura M, Lerdsirisuk P, Du Y, Ishikawa Y, Iwata R, Shidahara M, Ishiki A, Kikuchi A, Arai H, Kudo Y, Yanai K, Furumoto S, Okamura N. 18 F-SMBT-1: A selective and reversible positron-emission tomography tracer for monoamine oxidase-B imaging. J Nucl Med. 2021; 62: 253-258.
Lerdsirisuk P, Harada R, Hayakawa Y, Shimizu Y, Ishikawa Y, Iwata R, Kudo Y, Okamura N, Furumoto S. Synthesis and evaluation of 2-pyrrolopyridinylquinoline derivatives as selective tau PET tracers for the diagnosis of Alzheimer’s disease. Nucl Med Biol. 2020; 93: 11-18.
Hsu JL, Chen SH, Hsiao IT, Lu CS, Yen TC, Okamura N, Lin KJ, Weng YH. 18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty. Sci Rep. 2020; 10: 19410.
Huang KL, Hsiao IT, Ho MY, Hsu JL, Chang YJ, Chang TY, Liu CH, Chang CH, Wu YM, Wu KY, Wey SP, Yen TC, Okamura N, Lee TH, Lin KJ. Investigation of reactive astrogliosis effect on post-stroke cognitive impairment. J Neuroinflammation. 2020; 17: 308.
Bandaru SS, Khanday MA, Ibrahim N, Naganuma F, Vetrivelan R. Sleep-Wake Control by Melanin-Concentrating Hormone (MCH) Neurons: a Review of Recent Findings. Curr Neurol Neurosci Rep. 2020; 20: 55.
Yamada Y, Yoshikawa T, Naganuma F, Kikkawa T, Osumi N, Yanai K. Chronic brain histamine depletion in adult mice induced depression-like behaviours and impaired sleep-wake cycle. Neuropharmacology 2020; 175: 108179.
Jeong HJ, Lee H, Lee SY, Seo S, Park KH, Lee YB, Shin DJ, Kang JM, Yeon BK, Kang SG, Cho J, Seong JK, Okamura N, Villemagne VL, Na DL, Noh Y. [¹⁸F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment. J Clin Neurol. 2020; 16: 202-214.
Mairinger S, Filip T, Sauberer M, Flunkert S, Wanek T, Stanek J, Furtner S, Hutter-Paier B, Okamura N, Kuntner C. Plasma pharmacokinetic and metabolism of [18F]THK-5317 are dependent on sex. Nucl Med Biol. 2020; 84-85: 28-32.
Gersel Stokholm M, Iranzo A, Østergaard K, Serradell M, Otto M, Bacher Svendsen K, Garrido A, Vilas D, Fedorova TD, Santamaria J, Møller A, Gaig C, Hiraoka K, Brooks DJ, Okamura N, Borghammer P, Tolosa E, Pavese N. Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder. Eur J Neurol. 2020; 27: 644-652.
Kárpáti A, Yoshikawa T, Naganuma F, Matsuzawa T, Kitano H, Yamada Y, Yokoyama M, Futatsugi A, Mikoshiba K, Yanai K. Histamine H1 receptor on astrocytes and neurons controls distinct aspects of mouse behaviour. Sci Rep. 2019; 9: 16451.
Schönecker S, Brendel M, Palleis C, Beyer L, Höglinger GU, Schuh E, Rauchmann BS, Sauerbeck J, Rohrer G, Sonnenfeld S, Furukawa K, Ishiki A, Okamura N, Bartenstein P, Dieterich M, Bötzel K, Danek A, Rominger A, Levin J. PET imaging of astrogliosis and tau facilitates diagnosis of Parkinsonian syndromes. Front Aging Neurosci. 2019; 11: 249.
Jeon S, Kang JM, Seo S, Jeong HJ, Funck T, Lee SY, Park KH, Lee YB, Yeon BK, Ido T, Okamura N, Evans AC, Na DL, Noh Y. Topographical heterogeneity of Alzheimer’s disease based on MR imaging, tau PET, and amyloid PET. Front Aging Neurosci. 2019; 11: 211.
Nakamura T, Hiraoka K, Harada R, Matsuzawa T, Ishikawa Y, Funaki Y, Yoshikawa T, Tashiro M, Yanai K, Okamura N. Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. Pharmacol Res Perspect. 2019; 7: e00499.
Saito K, Kaiho Y, Tamii T, Nakamura T, Kameyama E, Yamauchi M. Intraoperative hemorrhage in revision total hip arthroplasty: a retrospective single-center study. J Anesth. 2019; 33: 399-407.
Kobayashi R, Hayashi H, Kawakatsu S, Okamura N, Yoshioka M, Otani K. Assessment of amyloid deposition in patients with probable REM sleep behavior disorder as a prodromal symptom of dementia with Lewy bodies using PiB-PET. Front Neurol. 2019; 10: 671.
Ezura M, Kikuchi A, Ishiki A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, Hiraoka K, Baba T, Sugeno N, Oshima R, Yoshida S, Kobayashi J, Kobayashi M, Tano O, Nakashima I, Mugikura S, Iwata R, Taki Y, Furukawa K, Arai H, Furumoto S, Tashiro M, Yanai K, Kudo Y, Takeda A, Aoki M. Longitudinal changes in 18 F-THK5351 positron emission tomography in corticobasal syndrome. Eur J Neurol. 2019; 26: 1205-1211.
Yoshikawa T,Nakamura T, Yanai K. Histamine N-Methyltransferase in the Brain. Int J Mol Sci.2019; 20: 737.
Naganuma F, Bandaru SS, Absi G, Chee MJ, Vetrivelan R. Melanin-concentrating hormone neurons promote rapid eye movement sleep independent of glutamate release. Brain Struct Funct.2019; 224: 99-110.
Kamei M, Otani Y, Hayashi H, Nakamura T, Yanai K, Furuta K, Tanaka S. Suppression of IFN-γ Production in Murine Splenocytes by Histamine Receptor Antagonists. Int J Mol Sci. 2018; 19: 4083.
Naganuma F, Bandaru SS, Absi G, Mahoney CE, Scammell TE, Vetrivelan R. Melanin-concentrating hormone neurons contribute to dysregulation of rapid eye movement sleep in narcolepsy. Neurobiol Dis.2018; 120: 12-20.
Yoon CW, Jeong HJ, Seo S, Lee SY, Suh MK, Heo JH, Lee YB, Park KH, Okamura N, Lee KM, Noh Y. 18F-THK5351 PET Imaging in Nonfluent-Agrammatic Variant Primary Progressive Aphasia. Dement Neurocogn Disord. 2018; 17: 110-119.
Tago T, Toyohara J, Harada R, Furumoto S, Okamura N, Kudo Y, Takahashi-Fujigasaki J, Murayama S, Ishii K. Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site. Ann Nucl Med. 2019; 33: 375-382.
Shigemoto Y, Sone D, Maikusa N, Okamura N, Furumoto S, Kudo Y, Ogawa M, Takano H, Yokoi Y, Sakata M, Tsukamoto T, Kato K, Sato N, Matsuda H. Association of deposition of tau and amyloid-β proteins with structural connectivity changes in cognitively normal older adults and Alzheimer’s disease spectrum patients. Brain Behav. 2018: e01145.
Yokoi T, Watanabe H, Yamaguchi H, Bagarinao E, Masuda M, Imai K, Ogura A, Ohdake R, Kawabata K, Hara K, Riku Y, Ishigaki S, Katsuno M, Miyao S, Kato K, Naganawa S, Harada R, Okamura N, Yanai K, Yoshida M, Sobue G. Involvement of the precuneus/posterior cingulate cortex is significant for the development of Alzheimer’s disease: a PET (THK5351, PiB) and resting fMRI study. Front Aging Neurosci. 2018; 10: 304.
Nai YH, Watanuki S, Tashiro M, Okamura N, Watabe H. Investigation of the quantitative accuracy of low-dose amyloid and tau PET imaging. Radiol Phys Technol. 2018; 11: 451-459.
Harada R, Okamura N, Furumoto S, Yanai K. Imaging protein misfolding in the brain using β-Sheet ligands. Front Neurosci. 2018; 12: 585.
Sedjahtera A, Gunawan L, Bray L, Hung LW, Parsons J, Okamura N, Villemagne VL, Yanai K, Liu XM, Chan J, Bush AI, Finkelstein DI, Barnham KJ, Cherny RA, Adlard PA. Targeting metals rescues the phenotype in an animal model of tauopathy. Metallomics. 2018; 10: 1339-1347.
Okamura N, Harada R, Ishiki A, Kikuchi A, Nakamura T, Kudo Y. The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging. 2018; 6: 305-316.
Kobayashi R, Hayashi H, Kawakatsu S, Ishiki A, Okamura N, Arai H, Otani K. [18F]THK-5351 PET imaging in early-stage semantic variant primary progressive aphasia: a report of two cases and a literature review. BMC Neurol. 2018; 18: 109.
Shigemoto Y, Sone D, Imabayashi E, Maikusa N, Okamura N, Furumoto S, Kudo Y, Ogawa M, Takano H, Yokoi Y, Sakata M, Tsukamoto T, Kato K, Sato N, Matsuda H. Dissociation of tau deposits and brain atrophy in early Alzheimer’s disease: A combined positron emission tomography/magnetic resonance imaging study. Front Aging Neurosci. 2018; 10: 223.
Huang KL, Hsu JL, Lin KJ, Chang CH, Wu YM, Chang TY, Chang YJ, Liu CH, Ho MY, Wey SP, Yen TC, Okamura N, Hsiao IT, Lee TH. Visualization of ischemic stroke-related changes on 18F-THK-5351 positron emission tomography. EJNMMI Res.2018; 8: 62.
Schöberl F, Levin J, Remi J, Goldschagg N, Eren O, Okamura N, Unterrainer M, Rominger A, Albert N, Brendel M. IgLON5: A case with predominant cerebellar tau deposits and leptomeningeal inflammation. Neurology.2018; 91: 180-182.
Ishiki A, Harada R, Kai H, Sato N, Totsune T, Tomita N, Watanuki S, Hiraoka K, Ishikawa Y, Funaki Y, Iwata R, Furumoto S, Tashiro M, Sasano H, Kitamoto T, Kudo Y, Yanai K, Furukawa K, Okamura N, Arai H. Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathol Commun. 2018; 6: 53.
Brendel M, Yousefi BH, Blume T, Herz M, Focke C, Deussing M, Peters F, Lindner S, von Ungern-Sternberg B, Drzezga A, Bartenstein P, Haass C, Okamura N, Herms J, Yakushev I, Rominger A. Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology. Front Aging Neurosci. 2018; 10: 174.
Leinonen V, Rauramaa T, Johansson J, Bottelbergs A, Tesseur I, van der Ark P, Pemberton D, Koivisto AM, Jääskeläinen JE, Hiltunen M, Herukka SK, Blennow K, Zetterberg H, Jokinen P, Rokka J, Helin S, Haaparanta-Solin M, Solin O, Okamura N, Kolb HC, Rinne JO. S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.J Alzheimers Dis.2018; 64: 171-179.
Chiotis K, Stenkrona P, Almkvist O, Stepanov V, Ferreira D, Arakawa R, Takano A, Westman E, Varrone A, Okamura N, Shimada H, Higuchi M, Halldin C, Nordberg A. Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain. Eur J Nucl Med Mol Imaging. 2018; 45: 1605-1617.
Chen J, Li Y, Pirraglia E, Okamura N, Rusinek H, de Leon MJ; Alzheimer’s Disease Neuroimaging Initiative. Quantitative evaluation of tau PET tracers 18F-THK5351 and 18F-AV-1451 in Alzheimer’s disease with standardized uptake value peak-alignment (SUVP) normalization. Eur J Nucl Med Mol Imaging. 2018; 45: 1596-1604.
Shimizu S, Imabayashi E, Takenoshita N, Okamura N, Furumoto S, Kudo Y, Matsuda H, Hanyu H. Case of progressive supranuclear palsy detected by tau imaging with [18F]THK-5351 before the appearance of characteristic clinical features. Geriatr Gerontol Int.2018; 18: 501-502.
Brendel M, Schönecker S, Höglinger G, Lindner S, Havla J, Blautzik J, Sauerbeck J, Rohrer G, Zach C, Vettermann F, Lang AE, Golbe L, Nübling G, Bartenstein P, Furukawa K, Ishiki A, Bötzel K, Danek A, Okamura N, Levin J, Rominger A. [18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy. Front Aging Neurosci.2018; 9: 440.
Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, Tago T, Tomita N, Watanuki S, Hiraoka K, Ishikawa Y, Funaki Y, Nakamura T, Yoshikawa T, Iwata R, Tashiro M, Sasano H, Kitamoto T, Yanai K, Arai H, Kudo Y, Okamura N. Correlations of 18F-THK5351 PET with post-mortem burden of tau and astrogliosis in Alzheimer’s disease. J Nucl Med. 2018; 59: 671-674.
Lee H, Seo S, Lee SY, Jeong HJ, Woo SH, Lee KM, Lee YB, Park KH, Heo JH, Yoon CW, Kang JM, Cho J, Okamura N, Furumoto S, Yanai K, Na DL, Ido T, Villemagne VL, Noh Y. [18F]-THK5351 PET Imaging in patients with semantic variant primary progressive aphasia. Alzheimer Dis Assoc Disord. 2018; 32: 62-69.
Brendel M, Wagner L, Levin J, Zach C, Lindner S, Bartenstein P, Okamura N, Rominger A. Perfusion-Phase [18F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration. J Alzheimers Dis Rep.2017; 1: 109-113.
Lemoine L, Gillberg PG, Svedberg M, Stepanov V, Jia Z, Huang J, Nag S, Tian H, Ghetti B, Okamura N, Higuchi M, Halldin C, Nordberg A. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther. 2017; 9: 96.
Naganuma F, Nakamura T, Yoshikawa T, Iida T, Miura Y, Kárpáti A, Matsuzawa T, Yanai A, Mogi A, Mochizuki T, Okamura N, Yanai K. Histamine N-methyltransferase regulates aggression and the sleep-wake cycle. Sci Rep. 2017; 7: 15899.
Yanai K, Yoshikawa T, Yanai A, Nakamura T, Iida T, Leurs R, Tashiro M. The clinical pharmacology of non-sedating antihistamines. Pharmacol Ther. 2017; 178: 148-156.
Betthauser TJ, Ellison PA, Murali D, Lao PJ, Barnhart TE, Furumoto S, Okamura N, Johnson SC, Engle JW, Nickles RJ, Christian BT. Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau. Appl Radiat Isot. 2017; 130: 230-237.
Kang JM, Lee SY, Seo S, Jeong HJ, Woo SH, Lee H, Lee YB, Yeon BK, Shin DH, Park KH, Kang H, Okamura N, Furumoto S, Yanai K, Villemagne VL, Seong JK, Na DL, Ido T, Cho J, Lee KM, Noh Y. Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer’s disease. Neurobiol Aging. 2017; 59: 210-219.
Sone D, Imabayashi E, Maikusa N, Okamura N, Furumoto S, Kudo Y, Ogawa M, Takano H, Yokoi Y, Sakata M, Tsukamoto T, Kato K, Matsuda H. Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer’s disease: A combined positron emission tomography/magnetic resonance imaging study. Alzheimers Dement (Amst). 2017; 9: 35-40.
Iida T, Yoshikawa T, Kárpáti A, Matsuzawa T, Kitano H, Mogi A, Harada R, Naganuma F, Nakamura T, Yanai K. JNJ10181457, a histamine H3 receptor inverse agonist, regulates in vivo microglial functions and improves depression-like behaviours in mice. Biochem Biophys Res Commun. 2017; 488: 534-540.
Shidahara M, Thomas BA, Okamura N, Ibaraki M, Matsubara K, Oyama S, Ishikawa Y, Watanuki S, Iwata R, Furumoto S, Tashiro M, Yanai K, Gonda K, Watabe H. A comparison of five partial volume correction methods for Tau and Amyloid PET imaging with [18F]THK5351 and [11C]PIB. Ann Nucl Med. 2017; 31: 563-569.
Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017; 9: 25.
Hsiao IT, Lin KJ, Huang KL, Huang CC, Chen HS, Wey SP, Yen TC, Okamura N, Hsu JL. Biodistribution and radiation dosimetry for the tau tracer 18F-THK-5351 in healthy human subjects. J Nucl Med. 2017; 58:1498-1503.
de Leon MJ, Li Y, Okamura N, Tsui WH, Saint Louis LA, Glodzik L, Osorio RS, Fortea J, Butler T, Pirraglia E, Fossati S, Kim HJ, Carare RO, Nedergaard M, Benveniste H, Rusinek H. CSF clearance in Alzheimer Disease measured with dynamic PET. J Nucl Med. 2017; 58: 1471-1476.
Okamura N, Yanai K. Applications of tau PET imaging. Nat Rev Neurol. 2017; 13: 197-198.
Furumoto S, Tago T, Harada R, Kudo Y, Okamura N. 18F-Labeled 2-arylquinoline derivatives for tau imaging: chemical, radiochemical, biological and clinical features. Curr Alzheimer Res.2017; 14: 178-185.
Arakawa Y, Nai Y, Shidahara M, Furumoto S, Seki C, Okamura N, Tashiro M, Kudo Y, Yanai K, Gonda K, Watabe H. Prediction of the clinical standardized uptake value ratio in amyloid PET imaging using a biomathematical modeling approach towards the efficient development of a radioligand. J Nucl Med.2017; 58: 1285-1292.
Neelamegam R, Yokell DL, Rice PA, Furumoto S, Kudo Y, Okamura N, El Fakhri G. A report of the automated radiosynthesis of the tau PET radiopharmaceutical, [18F]-THK-5351. J Labelled Comp Radiopharm.2017; 60: 140-146.
Betthauser T, Lao PJ, Murali D, Barnhart TE, Furumoto S, Okamura N, Stone CK, Johnson SC, Christian BT. In vivo comparison of tau radioligands 18F-THK-5351 and 18F-THK-5317. J Nucl Med. 2017; 58: 996-1002.
Ishiki A, Harada R, Okamura N, Tomita N, Rowe CC, Villemagne VL, Yanai K, Kudo Y, Arai H, Furumoto S, Tashiro M, Furukawa K. Tau imaging with [18F]THK-5351 in progressive supranuclear palsy. Eur J Neurol.2017; 24: 130-136.
Miura Y, Yoshikawa T, Naganuma F, Nakamura T, Iida T, Kárpáti A, Matsuzawa T, Mogi A, Harada R, Yanai K. Characterization of murine polyspecific monoamine transporters. FEBS Open Bio.2017; 7: 237-248.
Stepanov V, Svedberg M, Jia Z, Krasikova R, Lemoine L, Okamura N, Furumoto S, Mitsios N, Mulder J, Långström B, Nordberg A, Halldin C. Development of [11C]/[3H]THK-5351 – A potential novel carbon-11 tau imaging PET radioligand. Nucl Med Biol.2016; 46: 50-53.
Kikuchi A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, Hiraoka K, Baba T, Sugeno N, Oshima R, Yoshida S, Kobayashi J, Ezura M, Kobayashi M, Tano O, Mugikura S, Iwata R, Ishiki A, Furukawa K, Arai H, Furumoto S, Tashiro M, Yanai K, Kudo Y, Takeda A, Aoki M. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology. 2016; 87: 2309-2316.
Schönecker S, Brendel M, Huber M, Vollmar C, Huppertz HJ, Teipel S, Okamura N, Levin J, Rominger A, Danek A. Applied multimodal diagnostics in a case of presenile dementia. BMC Neurol. 2016; 16: 131.
Villemagne VL, Okamura N, Rowe CC. Untangling tau imaging. Alzheimers Dement (Amst). 2016; 4: 39-42.
Harada R, Furumoto S, Tago T, Furukawa K, Ishiki A, Tomita N, Iwata R, Tashiro M, Arai H, Yanai K, Kudo Y, Okamura N. Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351. Eur J Nucl Med Mol Imaging. 2016; 43: 2211-2218.
Lockhart SN, Baker SL, Okamura N, Furukawa K, Ishiki A, Furumoto S, Tashiro M, Yanai K, Arai H, Kudo Y, Harada R, Tomita N, Hiraoka K, Watanuki S, Jagust WJ. Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer’s disease patients measured using [18F]THK-5351. PLoS One. 2016; 11: e0158460.
Brendel M, Jaworska A, Probst F, Overhoff F, Korzhova V, Lindner S, Carlsen J, Bartenstein P, Harada R, Kudo Y, Haass C, van Leuven F, Okamura N, Herms J, Rominger Small-animal PET imaging of tau pathology with 18F-THK5117 in 2 transgenic mouse models. J Nucl Med.2016; 57:792-798.
Okamura N, Harada R, Furukawa K, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y. Advances in the development of tau PET radiotracers and their clinical applications. Ageing Res Rev.2016; 30:107-113.
Furukawa K, Ishiki A, Tomita N, Onaka Y, Saito H, Nakamichi T, Hara K, Kusano Y, Ebara M, Arata Y, Sakota M, Miyazawa I, Totsune T, Okinaga S, Okamura N, Kudo Y, Arai H. Introduction and overview of the special issue “Brain imaging and aging”: The new era of neuroimaging in aging research. Ageing Res Rev. 2016; 30:1-3.
Harada R, Furumoto S, Yoshikawa T, Ishikawa Y, Shibuya K, Okamura N, Ishiwata K, Iwata R, Yanai K. Synthesis and characterization of 18F-interleukin-8 using a cell-free translation system and 18F-fluoro-L-proline. J Nucl Med. 2016; 57: 634-639.
Harada R, Okamura N, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y. Characteristics of Tau and Its Ligands in PET Imaging. Biomolecules. 2016; 6: 7
Tago T, Furumoto S, Okamura N, Harada R, Adachi H, Ishikawa Y, Yanai K, Iwata R, Kudo Y. Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer’s Disease. J Nucl Med. 2016; 57: 608-14.
Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Tago T, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Funaki Y, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer’s Disease. J Nucl Med. 2016; 57: 208-214.